Floxuridine
生产企业:App pharmaceuticals llc, Bedford laboratories div ben venue laboratories inc,另有 1 家
Floxuridine is an antimetabolite used as palliative management for liver metastases of gastrointestinal malignancy.
Floxuridine is an antimetabolite used as palliative management for liver metastases of gastrointestinal malignancy.
Floxuridine rapidly undergoes catabolism to form 5-fluorouracil, which is the active component of the drug. 5-Fluorouracil primarily works by interfering with DNA synthesis; however, it may also inhibit the formation of fraudulent RNA via physical incorporation into the RNA. It is also an inhibitor of riboside phophorylase, preventing the utilization of pre-formed uracil in RNA synthesis. Floxuridine can also form 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP), which is the monophosphate of floxuridine that inhibits thymidylate synthetase that plays a role in the methylation of deoxyuridylic acid to thymidylic acid during DNA synthesis. FUDR-MP thus interferes with DNA synthesis.
For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。